The-202 A Allele of Insulin-Like Growth Factor Binding Protein-3 (IGFBP3) Promoter Polymorphism Is Associated with Higher IGFBP-3 Serum Levels and Better Growth Response to Growth Hormone Treatment in Patients with Severe Growth Hormone Deficiency


Autoria(s): COSTALONGA, Everlayny Fiorot; ANTONINI, Sonir R.; GUERRA-JUNIOR, Gil; MENDONCA, Berenice Bilharinho; ARNHOLD, Ivo J. P.; JORGE, Alexander A. L.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2009

Resumo

Context: Genetic factors that influence the response to recombinant human GH (rhGH) therapy remain mostly unknown. To date, only the GH receptor gene has been investigated. Objective: The aim of the study was to assess the influence of a polymorphism in the IGF-binding protein-3 (IGFBP-3) promoter region (-202 A/C) on circulating IGFBP-3 levels and growth response to rhGH therapy in children with GH deficiency (GHD). Design and Patients: -202 A/C IGFBP3 genotyping (rs2854744) was correlated with data of 71 children with severe GHD who remained prepubertal during the first year of rhGH treatment. Main Outcome Measures: We measured IGFBP-3 levels and first year growth velocity (GV) during rhGH treatment. Results: Clinical and laboratory data at the start of treatment were indistinguishable among patients with different -202 A/C IGFBP3 genotypes. Despite similar rhGH doses, patients homozygous for the A allele presented higher IGFBP-3 SD score levels and higher mean GV in the first year of rhGH treatment than patients with AC or CC genotypes (first year GV, AA = 13.0 +/- 2.1 cm/yr, AC = 11.4 +/- 2.5 cm/yr, and CC = 10.8 +/- 1.9 cm/yr; P = 0.016). Multiple linear regression analyses demonstrated that the influence of -202 A/C IGFBP3 genotype on IGFBP-3 levels and GV during the first year of rhGH treatment was independent of other variables. Conclusion: The -202 A allele of IGFBP3 promoter region is associated with increased IGFBP-3 levels and GV during rhGH treatment in prepubertal GHD children. (J Clin Endocrinol Metab 94: 588-595, 2009)

FAPESP Fundacao de Amparo a Pesquisa do Estado de Sao Paulo[05/04726-0]

FAPESP Fundacao de Amparo a Pesquisa do Estado de Sao Paulo[06/55763-5]

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico-CNPq[307951/06-5]

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico-CNPq[301246/95-5]

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico-CNPq[300938/06-3]

Identificador

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, v.94, n.2, p.588-595, 2009

0021-972X

http://producao.usp.br/handle/BDPI/24827

10.1210/jc.2008-1608

http://dx.doi.org/10.1210/jc.2008-1608

Idioma(s)

eng

Publicador

ENDOCRINE SOC

Relação

Journal of Clinical Endocrinology & Metabolism

Direitos

restrictedAccess

Copyright ENDOCRINE SOC

Palavras-Chave #IDIOPATHIC GH DEFICIENCY #WEIGHT HEIGHT VELOCITY #BRITISH CHILDREN 1965 #HISPANIC WHITE WOMEN #BREAST-CANCER RISK #FACTOR-I #ADULT HEIGHT #CIRCULATING LEVELS #DNA-SYNTHESIS #FINAL HEIGHT #Endocrinology & Metabolism
Tipo

article

original article

publishedVersion